Operates a data-driven risk exchange. Connects specialty insurance underwriters with risk capital partners. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 71% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 4.9× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 2% of them.
Analysts' average target sits 11% below today's price.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
The company sells $879.5M a year; the problem isn’t sales — it’s costs running above that number.
A loss of $1.4B against $879.5M in annual sales.
At the current pace of spending, the cash lasts about 1.9 years. After that, the company needs to find new money.
The stock trades 11% above the average analyst price target.
On our five-subject report card, ARX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ARX has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.